Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05382442 |
TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-05-19 |
Location
California, United States
China |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT05382741 |
TitleAdjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial | Phase
Phase 2
|
Date Added 2022-05-19 |
Location
Italy
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga |
Tags
MSS/ MMRp
|
| NCT ID NCT05350917 |
TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy | Phase
Phase 2
|
Date Added 2022-04-28 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05349890 |
TitlePersonalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | Phase
Phase 1
|
Date Added 2022-04-27 |
Location
Oregon, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
CDX-1140, Pembrolizumab, Keytruda |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05333809 |
TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-04-19 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Disitamab vedotin, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT05328908 |
TitleA Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer | Phase
Phase 3
|
Date Added 2022-04-14 |
Location
Arkansas, United States
California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga |
Tags
MSS/ MMRp
|
| NCT ID NCT05319314 |
TitleGCC19CART for Patients With Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2022-04-08 |
Location
California, United States
Colorado, United States Massachusetts, United States Michigan, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
GCC19CART |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05308446 |
TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | Phase
Phase 2
|
Date Added 2022-04-04 |
Location
Arizona, United States
California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT05299840 |
TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer | Phase
Not Applicable
|
Date Added 2022-03-29 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05292417 |
TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC | Phase
Phase 2
|
Date Added 2022-03-23 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, GM-CSF, Sintilimab |
Tags
MSS/ MMRp
|
